menu Search
Aartmin 850

Aartmin 850

metformin

Manufacturer:

Pinnacle Life Science

Distributor:

Khriz Pharma
Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing
Concise Prescribing Info
Contents
Metformin HCl
Indications/Uses
Type 2 DM, particularly in overwt patients, when dietary management & exercise alone does not result in adequate glycemic control. May be used as monotherapy or in combination w/ other oral antidiabetic agents (in adults only) or w/ insulin (in adults, adolescents & childn ≥10 yr).
Click to view Aartmin 850 detailed prescribing information
Dosage/Direction for Use
Adult w/ normal renal function (GFR ≥90 mL/min) Monotherapy & in combination w/ other oral antidiabetics: Initially 500 or 850 mg bid-tid. Adjust dose based on blood glucose measurements after 10-15 days. Max recommended dose: 3 g daily, taken as 3 divided doses. Combination w/ insulin: Initially 500 or 850 mg bid-tid, while insulin is adjusted based on blood glucose measurements. Adolescent & childn ≥10 yr Monotherapy & combination w/ insulin: Initially 500 or 850 mg once daily. Adjust dose based on blood glucose measurements after 10-15 days. Max recommended dose: 2 g daily, taken as 2-3 divided doses. Patient w/ renal impairment GFR 60-89 mL/min Total max daily dose: 3,000 mg divided in 2-3 daily doses, GFR 45-59 mL/min Total max daily dose: 2,000 mg divided in 2-3 daily doses, GFR 30-44 mL/min Total max daily dose: 1,000 mg divided in 2-3 daily doses.
Click to view Aartmin 850 detailed prescribing information
Overdosage
View Aartmin 850 overdosage for action to be taken in the event of an overdose.
Administration
Should be taken with food: Give during or after meals.
Contraindications
Hypersensitivity. Any type of acute or metabolic acidosis (eg, lactic acidosis, diabetic ketoacidosis). Diabetic pre-coma. Acute conditions w/ potential to alter renal function eg, dehydration, severe infection, shock. Disease which may cause tissue hypoxia (especially acute disease, or worsening of chronic disease) eg, decompensated heart failure, recent MI, shock. Hepatic insufficiency, acute alcohol intoxication, alcoholism. Severe renal failure (GFR <30 mL/min).
Click to view Aartmin 850 detailed prescribing information
Special Precautions
Risk of lactic acidosis; discontinue treatment in case of suspected symptoms. Assess GFR prior to treatment initiation & regularly thereafter. Regularly monitor cardiac & renal function in patients w/ stable chronic heart failure. Discontinue use prior to or at the time of imaging procedure w/ intravascular iodinated contrast agents & do not restart until at least 48 hr after, provided that renal function has been re-evaluated & found to be stable. Discontinue use at the time of surgery under general, spinal or epidural anesth; may be restarted no earlier than 48 hr following surgery or resumption of oral nutrition, provided that renal function has been re-evaluated & found to be stable. Risk of hypoglycemia w/ insulin or other oral antidiabetics (eg, sulfonylureas or meglitinides). Not recommended during pregnancy. Breast-feeding is not recommended during treatment. Caution when prescribing to childn 10-12 yr.
Click to view Aartmin 850 detailed prescribing information
Use In Pregnancy & Lactation
Click to view Aartmin 850 detailed prescribing information
Adverse Reactions
Nausea, vomiting, diarrhea, abdominal pain & loss of appetite. Taste disturbance.
Click to view Aartmin 850 detailed prescribing information
Drug Interactions
Increased risk of lactic acidosis w/ alcohol intoxication; intravascular administration of iodinated contrast agents; some medicinal products eg, NSAIDs including COX II inhibitors, ACE inhibitors, AIIA & diuretics (especially loop diuretics). May require more frequent blood glucose monitoring when combined w/ medicinal products w/ intrinsic hyperglycemic activity [eg, glucocorticoids (systemic & local) & sympathomimetics]. Reduced efficacy w/ OCT1 inhibitors (eg, verapamil). Increased GI absorption & efficacy w/ OCT1 inducers (eg, rifampicin). Decreased renal elimination leading to increased plasma conc w/ OCT2 inhibitors (eg, cimetidine, dolutegravir, ranolazine, trimethoprim, vandetanib, isavuconazole). Altered efficacy & renal elimination w/ inhibitors of both OCT1 & OCT2 (eg, crizotinib & olaparib).
Click to view Aartmin 850 detailed prescribing information
Storage
View Aartmin 850 storage conditions for details to ensure optimal shelf-life.
Description
View Aartmin 850 description for details of the chemical structure and excipients (inactive components).
Action
View Aartmin 850 mechanism of action for pharmacodynamics and pharmacokinetics details.
MIMS Class
Antidiabetic Agents
ATC Classification
A10BA02 - metformin ; Belongs to the class of biguanides. Used in the treatment of diabetes.
Regulatory Classification
Rx
Presentation/Packing
Form
Aartmin 850 FC tab 850 mg
Packing/Price
100's